Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
Benevolent
About
  2. Companies
  3. Benevolent
  4. Products
  5. Covid-19

Covid-19

SHARE

The emerging global threat from COVID-19 demanded immediate action. With cases rising rapidly, we set up a specialist team to use our AI-drug discovery platform to search for existing drugs — already proven safe — that could be repurposed to treat the virus. We are the only AI company to successfully identify a drug to treat COVID-19. Together by building bespoke drug repurposing workflow customisations, we used our Knowledge Graph and AI tools to search for approved drugs that could treat COVID-19, focusing on those that might block the viral infection process. We identified baricitinib — a drug owned by Eli Lilly and approved to treat rheumatoid arthritis — as the strongest treatment candidate. Our hypothesis sparked global clinical trials and the drug we identified is now approved by the FDA to treat COVID-19.

Most popular related searches
COVID 19
drug discovery platform
COVID-19 treatment
infection process
anti-inflammatory
inflammatory effect
rheumatoid arthritis
clinical trial
drug discovery
COVID-19 test
Rapid discovery
Scientists used our computational tools to interrogate the information in our Knowledge Graph and to rapidly visualise and explore the results. By combining human and machine intelligence, we arrived at a final hypothesis in just 48 hours.
Novel hypothesis
We extracted entirely new information from published research using our proprietary machine learning. Our novel hypothesis predicted that baricitinib could have antiviral activity, in addition to its previously known anti-inflammatory effect.
Effective treatment
Randomised control trial data showed the most significant reduction in mortality of any COVID-19 treatment tested to date: the COV-Barrier trial showed baricitinib reduced deaths by 38% across all patients, and by 46% in ventilated patients.